New York, NY -- (SBWIRE) -- 12/19/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Amarin Corporation plc (ADR) (NASDAQ:AMRN), Oi SA (ADR) (NYSE:OIBR), Generex Biotechnology Corporation (OTCMKTS:GNBT), BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX)
Amarin Corporation plc (ADR) (NASDAQ:AMRN) showed a volume of 2.62 million shares by the end of last trade whereas the average volume of the stock remained 5.07 million shares. The stock opened the session at $1.61 but then moved to $1.60. At that price, the stock showed a negative performance of -0.62%. Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company’s product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. In September 2011, it filed a New Drug Application (NDA), with the United States Food and Drug Administration (FDA). In December 2011, it commenced patient dosing in its cardiovascular outcomes study of AMR101,
Will AMRN Get Buyers Even After The Recent Rally? Find Out Here
Oi SA (ADR) (NYSE:OIBR) opened the session at $1.55 and closed the session at $1.56. The stock showed a negative performance of -0.64% in previous trading session. Traded with volume of 2.58 million shares in the prior session and the average volume of the stock remained 5.28 million shares. Oi SA, formerly Brasil Telecom SA, is a Brazil-based holding company engaged in the telecommunication sector. The Company is primarily involved in the provision of fixed telephony services in Brazilian states of Acre, Rondonia, Mato Grosso, Mato Grosso do Sul, Tocantins, Goias, Parana, Santa Catarina and Rio Grande do Sul. Additionally, it offers a range of integrated telecommunication services, including mobile telecommunication services, data transmission and Internet service provider (ISP) services, among others. The Company provides services to residential and corporate customers.
Has OIBR Found The Bottom And Ready To Gain Momentum? Find Out Here
Generex Biotechnology Corporation (OTCMKTS:GNBT) opened the session at $0.03 and closed the session at $0.0290. Traded with volume of 13.74 million shares in the prior session and the average volume of the stock remained 2.51 million shares. The beta of the stock remained 2.13. Generex Biotechnology Corporation is a Canada-based Company, which develops drug delivery systems and technologies for the treatment of diabetes. The Company has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity. Its buccal insulin spray product, Generex Oral-lyn is in Phase III clinical trials at several sites around the world. The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist device.
Is GNBT a Solid Investment at These Levels? Read This Report For Details
BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) the stock advanced 8.33% and finished the session at $7.02. Traded with volume of 2.48 million shares in the prior session and the average volume of the stock remained 837,143.00 shares. The beta of the stock remained 3.03. BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. BioCryst designs, optimizes and develops drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on therapeutic areas. Peramivir is its product, which is a neuraminidase inhibitor for the treatment of patients with influenza. The Company has two purine nucleoside phosphorylase (PNP) inhibitors that are in development,
Will BCRX Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)